Schmitt, LM; Nelson, M; Shaffer, RC; Erickson, CA. A near normal distribution of IQ in Fragile X Syndrome. Scientific Reports. 2024; 14:23058.

Sadhwani, A; Powers, S; Wheeler, A; Miller, H; Potter, SN; Peters, SU; Bacino, CA; Skinner, SA; Wink, LK; Erickson, CA; Bird, LM; Tan, WH. Developmental milestones and daily living skills in individuals with Angelman syndrome. Journal of Neurodevelopmental Disorders. 2024; 16:32.

Ethridge, LE; Pedapati, EV; Schmitt, LM; Norris, JE; Auger, E; De Stefano, LA; Sweeney, JA; Erickson, CA. Validating brain activity measures as reliable indicators of individual diagnostic group and genetically mediated sub-group membership Fragile X Syndrome. Scientific Reports. 2024; 14:22982.

Ammerman, RT; Erickson, CA. Innovative Approaches to Addressing Pediatric Mental Health. Pediatric Clinics of North America. 2024; 71:xvii-xix.

Erickson, CA; Perez-Cano, L; Pedapati, EV; Painbeni, E; Bonfils, G; Schmitt, LM; Sachs, H; Nelson, M; De Stefano, L; Westerkamp, G; Issachar, G; Blaettler, T; Hyvelin, JM; Durham, LA. Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD. Biomedicines. 2024; 12:1430.

ElSayed, Z; Suer, N; Westerkamp, G; Liu, JY; Miyakoshi, M; Erickson, C; Pedapati, E. CNN Brain Label-Maker: Computer Vision Based ICA Rejection EEG based System Architecture. Editor, Chun SA; Talbert DA. 2024; 37.

Takarae, Y; Zanesco, A; Erickson, CA; Pedapati, EV. EEG Microstates as Markers for Cognitive Impairments in Fragile X Syndrome. Brain Topography: journal of functional neurophysiology. 2024; 37:432-446.

Zappia, KJ; Shillington, A; Fosdick, C; Erickson, CA; Lamy, M; Dominick, KC. Neurodevelopmental Disorders Including Autism Spectrum Disorder and Intellectual Disability as a Risk Factor for Delayed Diagnosis of Catatonia. Journal of Developmental and Behavioral Pediatrics. 2024; 45:e137-e142.

Berry-Kravis, E; Abbeduto, L; Hagerman, R; Coffey, CS; Cudkowicz, M; Erickson, CA; McDuffie, A; Hessl, D; Ethridge, L; Tassone, F; Ecklund, D; Costigan, M; Huff, T; Pearson, B. Effects of AFQ056 on language learning in fragile X syndrome. The Journal of Clinical Investigation. 2024; 134:e171723.

Kaufmann, WE; Raspa, M; Bann, CM; Gable, JM; Harris, HK; Budimirovic, DB; Lozano, R; Berry-Kravis, E; Velinov, M; Talboy, AL; Uy, RS; Buchanan, C; Frazier, JA; Morris, SM. Latent Class Analysis Identifies Distinctive Behavioral Subtypes in Children with Fragile X Syndrome. Journal of Autism and Developmental Disorders. 2024; 54:725-737.

Protic, D; Breeze, E; Mendoza, G; Zafarullah, M; Abbeduto, L; Hagerman, R; Coffey, C; Cudkowicz, M; Durbin-Johnson, B; Ashwood, P; Talboy, A; Tartaglia, N; Veenstra-VanderWeele, J; Tassone, F. Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndrome. SAGE Open Medicine. 2024; 12:20503121241282401.

Liu, R; Pedapati, EV; Schmitt, LM; Shaffer, RC; Smith, EG; Dominick, KC; DeStefano, LA; Westerkamp, G; Horn, P; Sweeney, JA; Erickson, CA. Reliability of resting-state electrophysiology in fragile X syndrome. Biomarkers in Neuropsychiatry. 2023; 9:100070.

Schmitt, LM; Smith, EG; Pedapati, EV; Horn, PS; Will, M; Lamy, M; Barber, L; Trebley, J; Meyer, K; Heiman, M; West, KH J; Hughes, P; Ahuja, S; Erickson, CA. Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder. Scientific Reports. 2023; 13:5192.

Straub, D; Schmitt, LM; Boggs, AE; Horn, PS; Dominick, KC; Gross, C; Erickson, CA. A sensitive and reproducible qRT-PCR assay detects physiological relevant trace levels of FMR1 mRNA in individuals with Fragile X syndrome. Scientific Reports. 2023; 13:3808.

Rahmatullah, N; Schmitt, LM; De Stefano, L; Post, S; Robledo, J; Chaudhari, GR; Pedapati, E; Erickson, CA; Portera-Cailliau, C; Goel, A. Hypersensitivity to Distractors in Fragile X Syndrome from Loss of Modulation of Cortical VIP Interneurons. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2023; 43:8172-8188.

Shillington, A; Zappia, KJ; White, L; Fosdick, C; Erickson, CA; Lamy, M; Dominick, KC. Genetic syndromes are prevalent in patients with comorbid neurodevelopmental disorders and catatonia. American Journal of Medical Genetics, Part A. 2023; 191:2716-2722.

Dominick, KC; Zappia, K; Shillington, A; Fosdick, CM; Lamy, M; Erickson, CA. 27.4 Catatonia in Neurodevelopmental Disorders and the Creation of a Neurobehavioral Catatonia Specialty Clinic. Journal of the American Academy of Child and Adolescent Psychiatry. 2023; 62:s366-s367.

Kang, S; Jones, A; Shaffer, RC; Erickson, CA; Schmitt, LM. Developing improved outcome measures in FXS: Key stakeholder feedback. Research in Developmental Disabilities. 2023; 137:104502.

Shaffer, RC; Schmitt, LM; Reisinger, DL; Coffman, M; Horn, P; Goodwin, MS; Mazefsky, C; Randall, S; Erickson, C. Regulating Together: Emotion Dysregulation Group Treatment for ASD Youth and Their Caregivers. Journal of Autism and Developmental Disorders. 2023; 53:1942-1962.

Jones, A; Kang, S; Shaffer, RC; Erickson, CA; Schmitt, LM. Behavioral inflexibility in fragile X syndrome: Accounts from caregivers and self-advocates. Frontiers in Psychology. 2023; 14:1118652.

Norris, JE; Schmitt, LM; De Stefano, LA; Pedapati, EV; Erickson, CA; Sweeney, JA; Ethridge, LE. Neuropsychiatric feature-based subgrouping reveals neural sensory processing spectrum in female FMR1 premutation carriers: A pilot study. Frontiers in Integrative Neuroscience. 2023; 17:898215.

Beversdorf, DQ; Anagnostou, E; Hardan, A; Wang, P; Erickson, CA; Frazier, TW; Veenstra-VanderWeele, J. Editorial: Precision medicine approaches for heterogeneous conditions such as autism spectrum disorders (The need for a biomarker exploration phase in clinical trials - Phase 2m). Frontiers in Psychiatry. 2023; 13:1079006.

Schmitt, LM; Arzuaga, AL; Dapore, A; Duncan, J; Patel, M; Larson, JR; Erickson, CA; Sweeney, JA; Ragozzino, ME. Parallel learning and cognitive flexibility impairments between Fmr1 knockout mice and individuals with fragile X syndrome. Frontiers in Behavioral Neuroscience. 2023; 16:1074682.

Schmitt, LM; Li, J; Liu, R; Horn, PS; Sweeney, JA; Erickson, CA; Pedapati, EV. Altered frontal connectivity as a mechanism for executive function deficits in fragile X syndrome. Molecular Autism. 2022; 13:47.

Norris, JE; Destefano, LA; Schmitt, LM; Pedapati, EV; Erickson, CA; Sweeney, JA; Ethridge, LE. Hemispheric Utilization of Alpha Oscillatory Dynamics as a Unique Biomarker of Neural Compensation in Females with Fragile X Syndrome. ACS Chemical Neuroscience. 2022; 13:3389-3402.

Rosen, V; Blank, E; Lampert, E; Dominick, K; Will, M; Erickson, C; Pedapati, E; Lamy, M; Shaffer, R. Brief Report: Telehealth Satisfaction Among Caregivers of Pediatric and Adult Psychology and Psychiatry Patients with Intellectual and Developmental Disability in the Wake of Covid-19. Journal of Autism and Developmental Disorders. 2022; 52:5253-5265.

Berry-Kravis, E; Hagerman, R; Budimirovic, D; Erickson, C; Heussler, H; Tartaglia, N; Cohen, J; Tassone, F; Dobbins, T; Merikle, E; Sebree, T; Tich, N; Palumbo, JM; O’Quinn, S. A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX). Journal of Neurodevelopmental Disorders. 2022; 14:56.

Boggs, AE; Schmitt, LM; McLane, RD; Adayev, T; LaFauci, G; Horn, PS; Dominick, KC; Gross, C; Erickson, CA. Optimization, validation and initial clinical implications of a Luminex-based immunoassay for the quantification of Fragile X Protein from dried blood spots. Scientific Reports. 2022; 12:5617.

Jonak, CR; Pedapati, EV; Schmitt, LM; Assad, SA; Sandhu, MS; DeStefano, L; Ethridge, L; Razak, KA; Sweeney, JA; Binder, DK; Erickson, CA. Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome. Journal of Neurodevelopmental Disorders. 2022; 14:52.

Pedapati, EV; Schmitt, LM; Ethridge, LE; Miyakoshi, M; Sweeney, JA; Liu, R; Smith, E; Shaffer, RC; Dominick, KC; Gilbert, DL; Binder, DK; Lamy, M; Axford, M; Erickson, CA. Neocortical localization and thalamocortical modulation of neuronal hyperexcitability contribute to Fragile X Syndrome. Communications Biology. 2022; 5:442.

Pedapati, E; Ethridge, L; Sweeney, J; Miyakoshi, M; Schmitt, L; Liu, R; Wu, S; Gilbert, D; Horn, P; Erickson, CA. THALAMOCORTICAL DYSRHYTHMIA AS A UNIFYING MODEL OF NEUROPSYCHIATRIC AND NEUROSENSORY DYSFUNCTION IN FRAGILE X SYNDROME. Journal of the American Academy of Child and Adolescent Psychiatry. 2022; 61:s275-s276.

Lozano, R; Thompson, T; Dixon-Weber, J; Erickson, CA; Berry-Kravis, E; Williams, S; Smith, E; Frazier, JA; Rosselot, H; Farmer, C; Hessl, D. Observable Symptoms of Anxiety in Individuals with Fragile X Syndrome: Parent and Caregiver Perspectives. Genes. 2022; 13:1660.

Zhou, X; Feliciano, P; Shu, C; Wang, T; Astrovskaya, I; Hall, JB; Obiajulu, JU; Wright, JR; Murali, SC; Xu, SX; Cohen, C; Colombi, C; Diggins, C; Edmonson, C. Integrating de novo and inherited variants in 42,607 autism cases identifies mutations in new moderate-risk genes. Nature Genetics. 2022; 54:1305-1319.

Schmitt, LM; Sweeney, JA; Erickson, CA; Shaffer, R. Brief Report: Feasibility of the Probabilistic Reversal Learning Task as an Outcome Measure in an Intervention Trial for Individuals with Autism Spectrum Disorder. Journal of Autism and Developmental Disorders. 2022; 52:4191-4199.

Holley, AJ; Shedd, A; Boggs, A; Lovelace, J; Erickson, C; Gross, C; Jankovic, M; Razak, K; Huber, K; Gibson, JR. A sound-driven cortical phase-locking change in the Fmr1 KO mouse requires Fmr1 deletion in a subpopulation of brainstem neurons. Neurobiology of Disease. 2022; 170:105767.

Albizua, I; Charen, K; Shubeck, L; Talboy, A; Berry-Kravis, E; Kaufmann, WE; Stallworth, JL; Drazba, KT; Erickson, CA; Sweeney, JA; Sherman, SL; Warren, ST; Jin, P; Allen, EG. Descriptive analysis of seizures and comorbidities associated with fragile X syndrome. Molecular Genetics and Genomic Medicine. 2022; 10:e2001.

Yurkovic-Harding, J; Lisandrelli, G; Shaffer, RC; Dominick, KC; Pedapati, EV; Erickson, CA; Yu, C; Kennedy, DP. Children with ASD establish joint attention during free-flowing toy play without face looks. Current Biology. 2022; 32:2739-2746.e4.

Shillington, A; Lamy, M; Dominick, KC; Sorter, M; Erickson, CA; Hopkin, R. A Collaborative Psychiatric-Genetics Inpatient Care Delivery Model Improves Access to Clinical Genetic Evaluation, Testing, and Diagnosis for Patients With Neurodevelopmental Disorders. Frontiers in Genetics. 2022; 13:901458.

McDougle, CJ; Thom, RP; Ravichandran, CT; Palumbo, ML; Politte, LC; Mullett, JE; Keary, CJ; Erickson, CA; Stigler, KA; Mathieu-Frasier, L; Posey, DJ. A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder. Neuropsychopharmacology. 2022; 47:1263-1270.

Schmitt, LM; Dominick, KC; Liu, R; Pedapati, EV; Ethridge, LE; Smith, E; Sweeney, JA; Erickson, CA. Evidence for Three Subgroups of Female FMR1 Premutation Carriers Defined by Distinct Neuropsychiatric Features: A Pilot Study. Frontiers in Integrative Neuroscience. 2022; 15:797546.

Berry-Kravis, E; Filipink, RA; Frye, RE; Golla, S; Morris, SM; Andrews, H; Choo, T; Kaufmann, WE; FORWARD Consortium, . Seizures in Fragile X Syndrome: Associations and Longitudinal Analysis of a Large Clinic-Based Cohort. Frontiers in Pediatrics. 2021; 9:736255.

Yurkovic, JR; Lisandrelli, G; Shaffer, RC; Dominick, KC; Pedapati, EV; Erickson, CA; Kennedy, DP; Yu, C. Using head-mounted eye tracking to examine visual and manual exploration during naturalistic toy play in children with and without autism spectrum disorder. Scientific Reports. 2021; 11:3578.

Dominick, KC; Andrews, HF; Kaufmann, WE; Berry-Kravis, E; Erickson, CA. Psychotropic Drug Treatment Patterns in Persons with Fragile X Syndrome. Journal of Child and Adolescent Psychopharmacology. 2021; 31:659-669.

Gillentine, MA; Wang, T; Hoekzema, K; Rosenfeld, J; Liu, P; Guo, H; Kim, CN; De Vries, BB A; Vissers, LE L M; Nordenskjold, M; Amatya, A; Astrovskaya, I; Bashar, A; Brooks, E. Rare deleterious mutations of HNRNP genes result in shared neurodevelopmental disorders. Genome Medicine: medicine in the post-genomic era. 2021; 13:63.

Henneberry, E; Lamy, M; Dominick, KC; Erickson, CA. Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder. Journal of Autism and Developmental Disorders. 2021; 51:4370-4394.

White, LC; Law, JK; Daniels, AM; Toroney, J; Vernoia, B; Xiao, S; Feliciano, P; Chung, WK; Abbeduto, L; Aberbach, G; D’Ambrosi, S; Davis, S; Decius, N; Delaporte, J. Brief Report: Impact of COVID-19 on Individuals with ASD and Their Caregivers: A Perspective from the SPARK Cohort. Journal of Autism and Developmental Disorders. 2021; 51:3766-3773.

Harris, K; Lamy, M; Sorter, M; Frye, C; Terhune, L; Erickson, CA; Ruschman, G; Dominick, KC. Letter to the Editor: Chlorpromazine-Induced Skin Pigmentation in a Pediatric Patient. Journal of Child and Adolescent Psychopharmacology. 2021; 31:516-517.

Smith, EG; Pedapati, EV; Liu, R; Schmitt, LM; Dominick, KC; Shaffer, RC; Sweeney, JA; Erickson, CA. Sex differences in resting EEG power in Fragile X Syndrome. Journal of Psychiatric Research. 2021; 138:89-95.

Bal, VH; Wilkinson, E; White, LC; Law, JK; Feliciano, P; Chung, WK; Abbeduto, L; Aberbach, G; Aberle, S; Acampado, J; Davis, S; Decius, N; Delaporte, J; Dennis, B. Early Pandemic Experiences of Autistic Adults: Predictors of Psychological Distress. Autism Research: official journal of the International Society for Autism Research. 2021; 14:1209-1219.

Schaefer, TL; Ashworth, AA; Tiwari, D; Tomasek, MP; Parkins, EV; White, AR; Snider, A; Davenport, MH; Grainger, LM; Becker, RA; Gibson, JR; Huber, KM; Gross, C; Erickson, CA. GABAA Alpha 2,3 Modulation Improves Select Phenotypes in a Mouse Model of Fragile X Syndrome. Frontiers in Psychiatry. 2021; 12:678090.

Wink, LK; Reisinger, DL; Horn, P; Shaffer, RC; O'Brien, K; Schmitt, L; Dominick, KR; Pedapati, EV; Erickson, CA. Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study. Journal of Autism and Developmental Disorders. 2021; 51:1392-1399.

Miyakoshi, M; Schmitt, LM; Erickson, CA; Sweeney, JA; Pedapati, EV. Can We Push the "Quasi-Perfect Artifact Rejection " Even Closer to Perfection?. Frontiers in Neuroinformatics. 2021; 14:597079.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Mesoridazine. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Thioridazine. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Shillington, A; Lamy, M; Vawter-Lee, M; Erickson, C; Saal, H; Comoletti, D; Abell, K. Case Report: Is Catatonia a Clinical Feature of the Natural Progression of NLGN2-Related Neurodevelopmental Disorder?. Journal of Autism and Developmental Disorders. 2021; 51:371-376.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Quetiapine. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Alprazolam. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Erickson, CA; Wink, L; McDougle, CJ. Chlorpromazine. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Antidepressant Medications. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Doyle, CA; Wink, L; Erickson, CA; McDougle, CJ. Clomipramine. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Abnormal Involuntary Movement Scale. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Sertraline. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Serotonin Syndrome. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Thiothixene. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Aripiprazole. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Atypical Antipsychotics. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Nortriptyline. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Serotonin Reuptake Inhibitors (SRIs). Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Wang, T; Hoekzema, K; Vecchio, D; Wu, H; Sulovari, A; Coe, BP; Gillentine, MA; Wilfert, AB; Perez-Jurado, LA; Kvarnung, M; Zhou, X; Turner, TN; Bahl, E; Thomas, TR. Large-scale targeted sequencing identifies risk genes for neurodevelopmental disorders. Nature Communications. 2020; 11:4932.

Razak, KA; Dominick, KC; Erickson, CA. Developmental studies in fragile X syndrome. Journal of Neurodevelopmental Disorders. 2020; 12:13.

Westmark, CJ; Kniss, C; Sampene, E; Wang, A; Milunovich, A; Elver, K; Hessl, D; Talboy, A; Picker, J; Haas-Givler, B; Erickson, C; Velinov, M; Tartaglia, N; Berry-Kravis, EM. Soy-Based Infant Formula is Associated with an Increased Prevalence of Comorbidities in Fragile X Syndrome. Nutrients. 2020; 12:E3136.

Aman, MG; Norris, M; Kaat, AJ; Andrews, H; Choo, T; Chen, C; Wheeler, A; Bann, C; Erickson, C. Factor Structure of the Aberrant Behavior Checklist in Individuals with Fragile X Syndrome: Clarifications and Future Guidance. Journal of Child and Adolescent Psychopharmacology. 2020; 30:512-521.

Fombonne, E; Green Snyder, LA; Daniels, A; Feliciano, P; Chung, W; Abbeduto, L; Aberbach, G; Acampado, J; Ace, AJ; Albright, C; Gruber, AJ; Gulsrud, AC; Gunderson, J; Gunter, C. Psychiatric and Medical Profiles of Autistic Adults in the SPARK Cohort. Journal of Autism and Developmental Disorders. 2020; 50:3679-3698.

Lamy, M; Pedapati, EV; Dominick, KL; Wink, LK; Erickson, CA. Recent Advances in the Pharmacological Management of Behavioral Disturbances Associated with Autism Spectrum Disorder in Children and Adolescents. Pediatric Drugs. 2020; 22:473-483.

Berry-Kravis, E; Erickson, CA; Hagerman, R; Tartaglia, N; Cohen, J; Sebree, T; Gutterman, D; Tich, N; Dobbins, T; Palumbo, JM. Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome: Role of Methylation Status as a Correlate to Disease Severity and Prognostic Biomarker. Journal of the American Academy of Child and Adolescent Psychiatry. 2020; 59:s265.

Luu, S; Province, H; Berry-Kravis, E; Hagerman, R; Hessl, D; Vaidya, D; Lozano, R; Rosselot, H; Erickson, C; Kaufmann, WE; Budimirovic, DB. Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis. Brain Sciences. 2020; 10:E629.

Berry-Kravis, E; Horrigan, JP; Tartaglia, N; Hagerman, R; Kolevzon, A; Erickson, CA; Hatti, S; Snape, M; Yaroshinsky, A; Stoms, G; Glass, L; Jones, NE; Investigators, F. A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome. Pediatric Neurology. 2020; 110:30-41.

Reisinger, DL; Shaffer, RC; Tartaglia, N; Berry-Kravis, E; Erickson, CA. Delineating Repetitive Behavior Profiles across the Lifespan in Fragile X Syndrome. Brain Sciences. 2020; 10:E239.

Coffman, MC; Shaffer, RC; Schmitt, LM; Dominick, KC; Pedapati, E; Wang, A; Berry-Kravis, E; Tartaglia, N; Erickson, CA. Examination of Correlates to Health-Related Quality of Life in Individuals with Fragile X Syndrome. Brain Sciences. 2020; 10:E213.

Hoffmann, A; Wang, A; Berger, N; Cordeiro, L; Shaffer, R; Tartaglia, N; Erickson, C; Berry-Kravis, E. Language across the Lifespan in Fragile X Syndrome: Characteristics and Considerations for Assessment. Brain Sciences. 2020; 10:E212.

Fitzpatrick, SE; Schmitt, LM; Adams, R; Pedapati, EV; Wink, LK; Shaffer, RC; Sage, J; Weber, JD; Dominick, KC; Erickson, CA. Pediatric Quality of Life Inventory (PedsQL) in Fragile X Syndrome. Journal of Autism and Developmental Disorders. 2020; 50:1056-1063.

Reisinger, DL; Shaffer, RC; Horn, PS; Hong, MP; Pedapati, EV; Dominick, KC; Erickson, CA. Atypical Social Attention and Emotional Face Processing in Autism Spectrum Disorder: Insights From Face Scanning and Pupillometry. Frontiers in Integrative Neuroscience. 2020; 13:76.

Fombonne, EJ; Goin-Kochel, RP; O'Roak, BJ; Abbeduto, L; Aberbach, G; Acampado, J; Ace, AJ; Albright, C; Alessandri, M; Amaral, DG; Gruber, AJ; Gulsrud, AC; Gunderson, J; Gunter, C. Beliefs in vaccine as causes of autism among SPARK cohort caregivers. Vaccine. 2020; 38:1794-1803.

Shaffer, RC; Schmitt, L; Thurman, AJ; Abbeduto, L; Hong, M; Pedapati, E; Dominick, K; Sweeney, J; Erickson, C. The Relationship between Expressive Language Sampling and Clinical Measures in Fragile X Syndrome and Typical Development. Brain Sciences. 2020; 10:E66.

Schmitt, LM; Wang, J; Pedapati, EV; Thurman, AJ; Abbeduto, L; Erickson, CA; Sweeney, JA. A neurophysiological model of speech production deficits in fragile X syndrome. Brain Communications. 2020; 2:fcz042.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Aripiprazole. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2020.

Yurkovic, JR; Lisandrelli, G; Shaffer, RC; Dominick, KC; Pedapati, EV; Erickson, CA; Kennedy, DP; Yu, C. (2020) Examining Sustained Attention in Child-Parent Interaction: A Comparative Study of Typically Developing Children and Children with Autism Spectrum Disorder. cognitivesciencesociety.org. 329-335.